AEON Biopharma
http://www.aeonbiopharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AEON Biopharma
Korea Q3 Roundup: Mixed Results Amid Focus On Obesity, New Drugs
As Korean firms report quarterly earnings, Hanmi is stepping up the development of obesity drugs, Daewoong unveils plans to boost sales of in-house new drugs, GC Biopharma’s immunoglobulin undergoes the US approval process and Ildong has set up a new R&D-focused subsidiary.
Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success
Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.
Finance Watch: Apogee, Sagimet Launch First Big US IPOs Of The Summer
Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.
Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice